Latest Headlines

1. Quotient Sciences And Intrepid Labs Form Strategic Partnership To Accelerate AI-Guided Formulation Development 12/4/2025

   Under the new agreement, Quotient Sciences will have access to Intrepid’s machine learning model, ANDROMEDA, the first AI platform to develop and optimize clinical performance of drug products. The platform is designed to significantly reduce formulation development timelines, reduce API demands and increase formulation understanding, helping clients reach critical milestones faster and improve confidence in clinical success.

2. Large-Capacity Double Planetary Mixer Ideal For Highly Viscous Materials 11/26/2025

   ROSS recently completed the largest Double Planetary Mixer in its US history, a Model DPM-750 capable of mixing up to an impressive 750 gallons per batch and engineered with safety features for a Class I, Division 1, Group D hazardous environment. This heavy-duty mixer delivers the robust agitation required for ultra-high viscosity materials while adhering to demanding safety standards.

3. CSL To Build Out U.S. Plasma Capabilities Through $1.5B Investment 11/24/2025

   Global biopharma leader CSL (ASX:CSL; USOTC:CSLLY) today announced plans to expand its U.S. presence over the next five years, resulting in approximately US$1.5b in U.S. capital investments. These investments will generate hundreds of high-quality American jobs, strengthen U.S. manufacturing capabilities of plasma-derived therapies (PDTs), and help secure the U.S. medicine supply chain.  This reflects CSL’s commitment to meet the growing clinical need for immunoglobulin (Ig) over the long term.

4. Equipment Auction Announced For Sutro Biopharma Assets 11/24/2025

   December 15-16, 2025: Featuring late-model lab, R&D and manufacturing equipment surplus to future needs of Sutro BioPharma: spray dryer, chromatography systems, Westfalia seperators, HPLC’s & more.

5. Syntegon Delivers Strong Growth And Margin Expansion In Q3 2025 With Accelerating Pharma Momentum And Profitability Gains Across All Segments 11/21/2025

   Syntegon Group, a leading strategic partner to the pharmaceutical, biotech, and food industries, continued its strong growth and margin-improvement momentum in the third quarter of 2025, building on a successful first half of the year.

6. Novartis To Add Small Molecule & Fill/Finish Capacity With North Carolina Drug Manufacturing Investments 11/20/2025

   Novartis Gene Therapies, a division of Switzerland-based Novartis, one of the world’s largest pharmaceutical companies, plans to expand in the Research Triangle with $771 million of investments at multiple locations, creating its first biologics drug substance facility in the United States and adding small molecule manufacturing and new fill/finish capabilities.

7. Halozyme Completes Acquisition Of Elektrofi, Expanding Breadth Of Offerings In Drug Delivery 11/20/2025

   Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced the successful completion of its acquisition of Elektrofi, Inc. ("Elektrofi"), a biopharmaceutical company with a proprietary ultra-high concentration microparticle formulation technology for biologics, branded Hypercon™

8. Regeneron Announces Plans To Establish New Drug Manufacturing Facility In Saratoga Springs NY 11/19/2025

   Governor Kathy Hochul today announced that Regeneron Pharmaceuticals, a global leader in biotechnology founded in New York State, will create 1,000 new jobs as part of a $2 billion investment at its new facility in Saratoga Springs. The company plans to utilize a more than one million square foot property it recently purchased on Duplainville Road, which previously served as a printed material manufacturer. The project would encompass the design, reconstruction and fit-out of the existing space, with potential for additional expansion. Empire State Development has agreed to support Regeneron's plans and job creation goals with up to $35 million in performance-based Excelsior Jobs Program tax credits.

9. Novartis Expands U.S. footprint With New Radioligand Therapy Facility In California 11/12/2025

   Novartis, a leading global innovative medicines company, today announced the opening of a new 10,000-square-foot radioligand therapy (RLT) manufacturing facility in Carlsbad, California. This state-of-the-art site represents a key milestone in the company’s previously announced $23 billion investment in US infrastructure over the next five years.

10. AES Cleanroom Technology Establishes New Office In Research Triangle Park To Support Regional Drug Manufacturing Growth 11/11/2025

    AES Cleanroom Technology, an award-winning leader in modular cleanroom design and construction, has opened a new regional office in Research Triangle Park (RTP), reinforcing its commitment to serving the Southeast’s fast-growing life sciences, biotechnology, and advanced manufacturing sectors.